Evonik reported its 2013 financial results. The company reported group sales €12.9 billion, with a virtually stable organic sales trend. Adjusted EBITDA was €2.0 billion; the reduction from the very high prior-year figure was mainly price-induced. The adjusted EBITDA margin was 15.6 percent. “Evonik is now listed on the stock exchange and – since last summer’s divestment of the majority of shares in the real estate activities – a well-positioned and focused specialty chemicals company. In 2013 ...